Investment Analysts’ Weekly Ratings Changes for Novocure (NVCR)

Novocure (NASDAQ: NVCR) recently received a number of ratings updates from brokerages and research firms:

  • 1/25/2019 – Novocure was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 1/24/2019 – Novocure was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. “
  • 1/11/2019 – Novocure was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 1/10/2019 – Novocure was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 12/29/2018 – Novocure was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. “
  • 12/21/2018 – Novocure was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 12/13/2018 – Novocure was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 12/6/2018 – Novocure had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $51.00 price target on the stock. They wrote, “We currently model initial revenue for this indication starting in late 2019.””

NVCR stock opened at $48.17 on Wednesday. Novocure Ltd has a one year low of $19.20 and a one year high of $53.70. The firm has a market capitalization of $4.48 billion, a PE ratio of -68.81 and a beta of 2.86. The company has a quick ratio of 5.72, a current ratio of 6.17 and a debt-to-equity ratio of 1.30.

In related news, General Counsel Todd Christopher Longsworth sold 26,874 shares of the firm’s stock in a transaction dated Friday, January 25th. The shares were sold at an average price of $49.03, for a total value of $1,317,632.22. Following the completion of the sale, the general counsel now owns 36,305 shares in the company, valued at $1,780,034.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gabriel Leung sold 5,000 shares of the firm’s stock in a transaction dated Monday, December 10th. The shares were sold at an average price of $33.49, for a total transaction of $167,450.00. Following the completion of the sale, the director now owns 65,000 shares of the company’s stock, valued at approximately $2,176,850. The disclosure for this sale can be found here. Insiders sold a total of 869,589 shares of company stock valued at $38,239,749 in the last 90 days. Company insiders own 15.30% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Credit Suisse AG lifted its stake in shares of Novocure by 87.2% in the third quarter. Credit Suisse AG now owns 945,654 shares of the medical equipment provider’s stock valued at $49,552,000 after purchasing an additional 440,543 shares during the period. FMR LLC lifted its stake in shares of Novocure by 37.9% in the third quarter. FMR LLC now owns 10,845,246 shares of the medical equipment provider’s stock valued at $568,292,000 after purchasing an additional 2,983,125 shares during the period. Essex Investment Management Co. LLC lifted its stake in shares of Novocure by 2.8% in the third quarter. Essex Investment Management Co. LLC now owns 169,127 shares of the medical equipment provider’s stock valued at $8,862,000 after purchasing an additional 4,550 shares during the period. First Republic Investment Management Inc. acquired a new stake in shares of Novocure in the third quarter valued at about $1,609,000. Finally, WINTON GROUP Ltd acquired a new stake in shares of Novocure in the second quarter valued at about $202,000. Hedge funds and other institutional investors own 58.50% of the company’s stock.

Novocure Ltd. operates as an oncology company. It enages in developing its propriety technoclogy, Tumor Treating Fields, which uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth, and causing affected cancer cells to die. The company was founded by Yoram Palti in 2000 and is headquartered in St.

Recommended Story: Stock Symbol

Receive News & Ratings for Novocure Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply